Literature DB >> 21107314

Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: case study of a thorough QT study of asenapine.

S Chapel1, M M Hutmacher, H Bockbrader, R de Greef, R L Lalonde.   

Abstract

An assessment of the effects of asenapine on QTc interval in patients with schizophrenia revealed a discrepancy between the results obtained by two different methods: an intersection-union test (IUT) (as recommended in the International Conference on Harmonisation E14 guidance) and an exposure-response (E-R) analysis. Simulations were performed in order to understand and reconcile this discrepancy. Although estimates of the time-matched, placebo-corrected mean change in QTc from baseline (ddQTc) at peak plasma concentrations from the E-R analysis ranged from 2 to 5 ms per dose level, the IUT applied to simulated data from the E-R model yielded maximum ddQTc estimates of 7-10 ms for the various doses of asenapine. These results indicate that the IUT can produce biased estimates that may induce a high false-positive rate in individual thorough QTc trials. In such cases, simulations from an E-R model can aid in reconciling the results from the two methods and may support the use of E-R results as a basis for labeling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21107314     DOI: 10.1038/clpt.2010.220

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

Review 1.  Asenapine: A Review in Schizophrenia.

Authors:  Greg L Plosker; Emma D Deeks
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

2.  Estimation of QT interval prolongation through model-averaging.

Authors:  Peter L Bonate
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-04-18       Impact factor: 2.745

3.  Cardiac risk assessment based on early Phase I data and PK-QTc analysis is concordant with the outcome of thorough QTc trials: an assessment based on eleven drug candidates.

Authors:  Puneet Gaitonde; Yeamin Huh; Borje Darpo; Georg Ferber; Günter Heimann; James Li; Kaifeng Lu; Bernard Sebastien; Kuenhi Tsai; Steve Riley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-10-30       Impact factor: 2.745

4.  Postoperative QT interval prolongation in patients undergoing noncardiac surgery under general anesthesia.

Authors:  Peter Nagele; Swatilika Pal; Frank Brown; Jane Blood; J Philipp Miller; Joshua Johnston
Journal:  Anesthesiology       Date:  2012-08       Impact factor: 7.892

5.  Losmapimod concentration-QT relationship in healthy volunteers: meta-analysis of data from six clinical trials.

Authors:  Shuying Yang; Misba Beerahee
Journal:  Eur J Clin Pharmacol       Date:  2013-01-17       Impact factor: 2.953

Review 6.  The role of concentration-effect relationships in the assessment of QTc interval prolongation.

Authors:  Nicholas P France; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

7.  A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer.

Authors:  Richard M Lush; Amita Patnaik; Daniel Sullivan; Kyriakos P Papadopoulos; Michele Trucksis; Jacqueline McCrea; Kristine Cerchio; Xiaodong Li; Mark Stroh; Diana Selverian; Keith Orford; Scot Ebbinghaus; Nancy Agrawal; Marian Iwamoto; John A Wagner; Anthony Tolcher
Journal:  Cancer Chemother Pharmacol       Date:  2012-08-10       Impact factor: 3.333

8.  Role of sublingual asenapine in treatment of schizophrenia.

Authors:  Leslie Citrome
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-26       Impact factor: 2.570

Review 9.  Top-down, Bottom-up and Middle-out Strategies for Drug Cardiac Safety Assessment via Modeling and Simulations.

Authors:  Zofia Tylutki; Sebastian Polak; Barbara Wiśniowska
Journal:  Curr Pharmacol Rep       Date:  2016-04-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.